Cargando…

The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study

BACKGROUND: Prediction of acute kidney transplant rejection remains imperfect despite several known risk factors. There is an increasing appreciation of the potential importance of the vitamin D pathway in immunological disease and transplantation. OBJECTIVE: The purpose of this study was to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmerman, Deborah, House, Andrew A., Kim, S. Joseph, Booth, Ronald A., Zhang, Tinghua, Ramsay, Tim, Knoll, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406125/
https://www.ncbi.nlm.nih.gov/pubmed/28491335
http://dx.doi.org/10.1177/2054358117699822
_version_ 1783231911700725760
author Zimmerman, Deborah
House, Andrew A.
Kim, S. Joseph
Booth, Ronald A.
Zhang, Tinghua
Ramsay, Tim
Knoll, Greg
author_facet Zimmerman, Deborah
House, Andrew A.
Kim, S. Joseph
Booth, Ronald A.
Zhang, Tinghua
Ramsay, Tim
Knoll, Greg
author_sort Zimmerman, Deborah
collection PubMed
description BACKGROUND: Prediction of acute kidney transplant rejection remains imperfect despite several known risk factors. There is an increasing appreciation of the potential importance of the vitamin D pathway in immunological disease and transplantation. OBJECTIVE: The purpose of this study was to determine the association of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with acute rejection. DESIGN: This was a prospective cohort study. SETTING: Three academic adult kidney transplant programs in Ontario, Canada, were chosen. PATIENTS: All consecutive adult patients at the 3 institutions who received a solitary kidney transplant, were able to provide written informed consent, and planned to be followed at the same center post-operatively were included. MEASUREMENTS: Serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were measured at baseline, 3, and 6 months post-transplantation. Acute rejection was classified using Banff criteria. METHODS: The co-primary outcome was the association between 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D and time to first occurrence of biopsy-proven acute rejection (BPAR) within the first year after kidney transplantation. Cox proportional hazards models were fitted taking into account the time-varying nature of serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. RESULTS: From 556 screened patients, data on 327 kidney transplant recipients are included. First BPAR occurred in 54 (16.5%) patients. In adjusted Cox proportional hazards models, the serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D was not associated with acute renal transplant rejection (hazard ratio 1.00; 95% [confidence interval] CI, 0.87-1.14, per 10 nmol/L increase, and hazard ratio 0.97; 95% CI, 0.84-1.12, per 10 pmol/L increase, respectively). LIMITATIONS: Given the observational design, we cannot rule out the possibility of residual confounding that limited our ability to detect a clinically significant effect of vitamin D metabolites on acute rejection. CONCLUSIONS: A low serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D is not associated with an increased risk of acute kidney transplant rejection following kidney transplantation.
format Online
Article
Text
id pubmed-5406125
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-54061252017-05-10 The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study Zimmerman, Deborah House, Andrew A. Kim, S. Joseph Booth, Ronald A. Zhang, Tinghua Ramsay, Tim Knoll, Greg Can J Kidney Health Dis Original Research Article BACKGROUND: Prediction of acute kidney transplant rejection remains imperfect despite several known risk factors. There is an increasing appreciation of the potential importance of the vitamin D pathway in immunological disease and transplantation. OBJECTIVE: The purpose of this study was to determine the association of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with acute rejection. DESIGN: This was a prospective cohort study. SETTING: Three academic adult kidney transplant programs in Ontario, Canada, were chosen. PATIENTS: All consecutive adult patients at the 3 institutions who received a solitary kidney transplant, were able to provide written informed consent, and planned to be followed at the same center post-operatively were included. MEASUREMENTS: Serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were measured at baseline, 3, and 6 months post-transplantation. Acute rejection was classified using Banff criteria. METHODS: The co-primary outcome was the association between 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D and time to first occurrence of biopsy-proven acute rejection (BPAR) within the first year after kidney transplantation. Cox proportional hazards models were fitted taking into account the time-varying nature of serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. RESULTS: From 556 screened patients, data on 327 kidney transplant recipients are included. First BPAR occurred in 54 (16.5%) patients. In adjusted Cox proportional hazards models, the serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D was not associated with acute renal transplant rejection (hazard ratio 1.00; 95% [confidence interval] CI, 0.87-1.14, per 10 nmol/L increase, and hazard ratio 0.97; 95% CI, 0.84-1.12, per 10 pmol/L increase, respectively). LIMITATIONS: Given the observational design, we cannot rule out the possibility of residual confounding that limited our ability to detect a clinically significant effect of vitamin D metabolites on acute rejection. CONCLUSIONS: A low serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D is not associated with an increased risk of acute kidney transplant rejection following kidney transplantation. SAGE Publications 2017-04-10 /pmc/articles/PMC5406125/ /pubmed/28491335 http://dx.doi.org/10.1177/2054358117699822 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Zimmerman, Deborah
House, Andrew A.
Kim, S. Joseph
Booth, Ronald A.
Zhang, Tinghua
Ramsay, Tim
Knoll, Greg
The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title_full The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title_fullStr The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title_full_unstemmed The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title_short The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study
title_sort risk of acute rejection following kidney transplant by 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d status: a prospective cohort study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406125/
https://www.ncbi.nlm.nih.gov/pubmed/28491335
http://dx.doi.org/10.1177/2054358117699822
work_keys_str_mv AT zimmermandeborah theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT houseandrewa theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT kimsjoseph theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT boothronalda theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT zhangtinghua theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT ramsaytim theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT knollgreg theriskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT zimmermandeborah riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT houseandrewa riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT kimsjoseph riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT boothronalda riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT zhangtinghua riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT ramsaytim riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy
AT knollgreg riskofacuterejectionfollowingkidneytransplantby25hydroxyvitamindand125dihydroxyvitamindstatusaprospectivecohortstudy